Positives

• Unlike triptans, ubrogepant lacks vasoconstrictive properties, making it a safer acute migraine option for patients with cardiovascular concerns — relevant for Long COVID patients with myocarditis history or POTS PMC.
  
  

Negatives

• A migraine patient who had used Imitrex, ubrogepant, and Advil before her COVID-19 infection found this regimen less effective afterward, and was switched to Botox every three months before noticing her migraines became more tolerable PMC.
  
  

Hurdles & Side Effects

• The most reported adverse effects of ubrogepant are nausea (5.7% vs 3.5% on placebo), somnolence (3.4% vs 2.5%), and dizziness (3.2% vs 2.5%) — generally mild and self-limited Ubrelvy PI.
  
  
• List price is roughly $1,000 for a 10-tablet supply; insurance authorization typically requires documented failure or contraindication to triptans, and ubrogepant is contraindicated with strong CYP3A4 inhibitors Drugs.com.